标题
Investigational CD33-targeted therapeutics for acute myeloid leukemia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 4, Pages 339-348
出版商
Informa UK Limited
发表日期
2018-03-14
DOI
10.1080/13543784.2018.1452911
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
- (2018) Colin E. Correnti et al. LEUKEMIA
- Gemtuzumab ozogamicin in acute myeloid leukemia
- (2017) C D Godwin et al. LEUKEMIA
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
- (2017) Christian Kellner et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Chimeric antigen receptor T cell therapy: 25years in the making
- (2016) Saar Gill et al. BLOOD REVIEWS
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
- (2016) U. Reusch et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
- (2016) M. L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
- (2016) Armin Rashidi et al. Expert Review of Hematology
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia
- (2015) O. Wolach et al. CLINICAL CANCER RESEARCH
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Quan-shun Wang et al. MOLECULAR THERAPY
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in Anticancer Immunotoxin Therapy
- (2015) C. Alewine et al. ONCOLOGIST
- The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
- (2015) Kimberly H. Harrington et al. PLoS One
- T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
- (2015) G S Laszlo et al. Blood Cancer Journal
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Christoph Schliemann et al. Cancer Immunology Research
- Immunotoxins for leukemia
- (2014) A. S. Wayne et al. BLOOD
- Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
- (2014) G. Romain et al. BLOOD
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
- (2014) A. E. Frankel et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
- (2014) C. O'Hear et al. HAEMATOLOGICA
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
- (2014) I Pizzitola et al. LEUKEMIA
- 5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
- (2014) May Kung Sutherland et al. mAbs
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
- (2014) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
- (2013) A. Mardiros et al. BLOOD
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
- (2013) Sarah Tettamanti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
- (2013) Roland Walter Frontiers in Bioscience-Landmark
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
- (2013) K. L. Gutbrodt et al. Science Translational Medicine
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Antibody-Based Immunotherapy of Cancer
- (2012) Louis M. Weiner et al. CELL
- Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands
- (2012) W. K. Chan et al. CLINICAL CANCER RESEARCH
- RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
- (2012) Fionnuala McAleese et al. Future Oncology
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
- (2012) G. Borthakur et al. HAEMATOLOGICA
- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
- (2012) M. A. Sekeres et al. HAEMATOLOGICA
- T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
- (2012) M Aigner et al. LEUKEMIA
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Sequential Cytarabine and -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
- (2010) T. L. Rosenblat et al. CLINICAL CANCER RESEARCH
- Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors
- (2010) V. Marin et al. HAEMATOLOGICA
- Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
- (2010) May Kung Sutherland et al. mAbs
- Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
- (2009) Azra Raza et al. LEUKEMIA & LYMPHOMA
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started